🇺🇸 FDA
Patent

US 11026931

Methods for the administration of certain VMAT2 inhibitors

granted A61KA61K31/4375A61K31/4738

Quick answer

US patent 11026931 (Methods for the administration of certain VMAT2 inhibitors) held by Neurocrine Biosciences, Inc. expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/4375, A61K31/4738, A61K31/56, A61K9/0053